Background; To compare characteristics, treatment and outcome of patients ^70 years with patients <70 years in a population-based non-Hodgkin's lymphoma (NHL) registry.
Introduction
The treatment of non-Hodgkin's lymphomas (NHL) in elderly patients is controversial. The elderly are often excluded from clinical trials, and studies regarding tolerance and efficacy of chemotherapy in the elderly are conflicting in their conclusions [1] [2] [3] . Selection bias might play a role in these discrepant results.
From a population-based registry, information is collected on all new cases in a geographically-defined region. Analysis of such a registry gives unbiased insight into the behaviour and outcome of a disease with respect to both biological characteristics [4] and treatment decisions. In Western populations the elderly form a growing fraction and this pertains especially to the elderly with NHL, because the incidence of these disorders sharply increases with age [4] [5] [6] . Analysis of this disease and its outcome in the elderly is important for future approaches. Because major difficulties arise in treating patients older than 70 [7, 8] , and a change from treatment with curative intent to palliative intent might therefore be considered [8] , we decided to define the elderly as patients ^ 70 years and compare this group with patients < 70 years.
Patients and methods
After establishment of consensus on staging and treatment by specialists from 15 hospitals and nine pathology laboratories in the Comprehensive Cancer Center West (CCCW) in the western parts of the Netherlands, all new cases with NHL were registered from June 1981 until December 1989. In this period the CCCW covered a population of 1.6 million inhabitants. The NHL Study Group defined the variables to be collected and designed the registration forms, so this is a prospective registration study. A panel of hematopathologists confirmed the histological diagnosis and classification. The classification was based on the Kiel classification [9] and grading was according to the National Cancer Institute Working Formulation for Clinical Usage [10] . In the 1990s all cases were reviewed and reclassified according to the updated Kiel [11] and R.E.A.L. Classifications [12] , Not included in the registry were cases of primary cutaneous T-cell lymphoma, classical chronic lymphocytic leukemia, acute lymphoblastic leukemia, multiple myeloma, plasmocytoma, and a post-mortem diagnosis of NHL. Staging was based on the Ann Arbor system [13] with a modification according to Musshofffor the extranodal stage II gastrointestinal lymphomas [14] . Complete staging comprised history focused on B-symptoms, physical examination, chest X-ray, bonemarrow biopsy and abdominal CT-scan. Ultrasound examination and isotope scanning of the liver and spleen and/or lymphangiography in combination with the isotope scanning were allowed in the early years of this registry [15] .
The extent of the lymphoma at presentation was divided into three groups: nodal, extranodal and extensive. The primary nodal lymphomas presented in lymph nodes, Waldeyer's ring, spleen or bone marrow; primary extranodal lymphomas presented at other sites with or without local lymph node involvement; and extensive presentation meant both extranodal and distant nodal sites [16] .
Although consensus on treatment was reached within the NHL Study Group of the CCCW, the choice of treatment was the responsibility of the local physician. For this study, the use of chemotherapy was divided between two groups: one with an anthracycline and the other without (mitoxantrone-based chemotherapy was not considered among the anthracyclines).
The age-adjusted International Prognostic Index (IPI) as described for patients with aggressive lymphomas [17] could not be applied as such, because it is defined for age 60 years and over, while in this cohort elderly was defined as 70 years or older. We performed an analysis using the remaining three variables as originally analysed for the IPI: serum lactate dehydrogenase (LDH) (normal or above normal), Karnofski index (;*80 or <80), stage (I and II or III and IV) and number of extranodal localisations (0 and 1 or > 2).
Statistical analyses were performed using chi-square tests to compare percentages in cross tabulations and the log-rank test to compare Kaplan-Meier survival curves. Two-sided comparisons were performed and due to multiple comparison considerations P < 0.01 was considered significant.
Overall survival was calculated from diagnosis until death (all causes, event) or last follow-up (censored). Disease-free survival was calculated from date of complete remission until recurrence or death (event) or until last contact when relapse-free alive (censored).
Prognostic factors for survival were identified by a stepwise performed Cox-regression analysis.
For this analysis the data until January 1997 were used. Yearly follow-up is still ongoing.
Results

Demographic data
From June 1981 until December 1989,1168 cases of NHL were registered. This means an average annual incidence rate of 8.6 per 10 5 individuals. Four hundred seventy- seven (41%) of the patients were 70 years old or older and 202 of them were men (42%). Among the elderly the median age was 77.6 (range 70-96) years. At last followup for this report 295 patients (25%) were alive; among the elderly this was 11% and among the patients below 70 years 35%. Among these survivors the median follow-up for the elderly was 92 months (range 67-169) and for the younger group 106 months (range 66-180).
Patient characteristics
The distribution of localisation, stage, bulk of disease and serum LDH did not differ significantly among the two age groups, whereas the distribution of sex, histological grade and Karnofski index showed significant differences (P < 0.001) as shown in Table 1 . There were 228 incompletely staged patients, of whom 144 were elderly. The missing staging procedure was often the bone marrow biopsy and in the elderly this contributed by 74% to the incomplete staging. Intermediate-grade histology was most common, especially in the elderly. The distribution of different lymphomas according to the R.E.A.L. Classification for both age groups is given 66 (10) 11 (2) 122 (18) 28 (4) 12 (2) 24 (3) 21 (3) 218 (32) 42 (6) 6 (1) 30 (4) 17 (2) 7 (1) 15 (2) 71 (10) n (%) 59 (12) 9 (2) 49 (10) 15 (3) 8 (2) 9 (2) 20 (4) 174 (36) 37 (8) 21 (4) 4 (1) 689 (100) 52 (8) 637 (92) 168 (26) 241 (38) 483 (76)' 303 (63) 179 (37) * Of four cases (three elderly) the unknown Ul_l n l l v * T ! ! • in Table 2 . The percentage of elderly patients with follicle center follicular grade 1-2 lymphomas was less than in the younger age group and the percentage with diffuse large B-cell lymphomas was more, as was to be expected from the difference between the two age groups in W.F. grading.
Treatment characteristics
Ninety-two elderly patients (19%) received no treatment at all. Of these, 38% had low-grade histology.
Three hundred eighty-four elderly patients (81%) were treated. Table 3 shows the distribution of the treatment components of surgery, radiotherapy and chemotherapy among the two age groups. The involvement of surgery mostly meant stage I-II disease (75%). Among the elderly patients to whom surgery was applied 21 (23%) presented with nodal localisation, in which case surgery was most probably part of the diagnostic procedure. Although the percentages of those receiving chemotherapy were almost the same in the two age groups, the elderly received far less anthracycline-based chemotherapy (26% vs. 63%). 'Surgery-alone' was applied to 38 (10%) elderly patients, 'radiotherapy-alone' to 64 (17%) and 'chemotherapy-alone' to 193 (50%) elderly patients.
Complete remission
Three hundred eighty-four elderly patients received treatment, 147 (38%) of whom were in complete remission at some point during their illness. This differed significantly from the younger group where 59% of the 637 treated patients reached complete remission (P < 0.001). Table 3 compares complete remission percentages for the different treatment modalities. The treatment modality surgery was excluded from the analysis because in some instances surgery played the role of diagnostic procedure only. Each treatment modality resulted in significantly less CR% in the elderly. Table 4 compares for treated patients only the complete remission rates of the two age groups for the three WF 
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Figure la. Overall survival according to histological grade for both age groups. The two age categories are statistically significantly different for each grade by the log-rank test (P < 0.001).
not differ significantly from the younger group, by which both age groups fared badly. Patients with high-grade MALT lymphomas also did not differ significantly, but in this subtype the elderly fared well. The overall survival curves for patients with follicle cente follicular grade 1-2 lymphomas and for patients with diffuse large B-cell lymphomas are given in Figures lb and lc. The cause of death was documented in 90% of the deceased patients (n = 873). Four categories were considered: lymphomarelated, treatment-related toxicity, other malignancy, and concomitant disease. In the elderly these categories contributed to death in, respectively, 62%, 8%, 7% and 23%,
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Follicle center folllcular grade 1-2 versus 69%, 9%, 7% and 15%, respectively, for the younger age group. This is marginally significantly different: P -0.04.
Disease-free survival
The disease-free survival at five years of the two age groups with respect to the previously-used subgroups is given in Table 6 . Once complete remission was achieved, there was no significant difference in disease-free survival at five years between the two age groups. The corresponding curves are shown in Figures Id, le using the variables of serum LDH, Karnofski index, stage and number of extranodal sites. Among the elderly patients (n -269) there were 60 (22%) with missing values regarding these variables, leaving 209 cases for the analysis. In a Cox's regression analysis the number of extranodal sites was no independent prognostic factor for overall survival, as was reported for the age-adjusted IPI [17] . The relative risk of death for the variables stage, serum LDH and Karnofski index is given in Table 7 . The number of risk factors at presentation was clearly predictive for the patient to be at low risk of death (no risk factor), low/intermediate risk of death (one risk factor), intermediate/high risk of death (two risk factors) or high risk of death (three risk factors). Table 8 gives for each index value the number of patients and the median survival time in months with respect to both age groups. The corresponding survival curves (not shown) demonstrated the same distinction. An analysis for the elderly with low-grade histology (n = 111) was also performed. In 29 cases values were missing, leaving 82 cases for the analysis. Only the variables Karnofski index and number of extranodal sites showed significance as independent prognostic factors of overall survival (data not shown). 100   75 50 . 
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Figure Id. Disease-free survival according to histological grade for both age groups.
Discussion
The age limit above which the 'elderly patient' is defined varies in most studies from 60 to 70 years. More than 50% of cancers occur above the age of 65 years [1, 2, 4, 18] , and 18%-38% of non-Hodgkin's lymphoma is diagnosed in the elderly [1, 2, 4, 19] . Because of ageing, the elderly will represent a growing fraction of patients, who will usually be excluded from trials. The proportion of elderly patients will therefore be higher in a populationbased registry [4] . In the current registry 41% of the patients were 70 years old or older. The preponderance of female patients among the elderly (58%) could be expected from the female predominance in this age group. Data from the Central Bureau of Statistics in the Netherlands showed for 1989 an elderly population of 1,270,562 of whom 63% were female [20] . When the characteristics of this patient population are compared with the LYFO registry from West Denmark [4] , also population-based, there are differences. The CCCW registry shows a significantly different distribution of histological grade between the two age groups, with more patients with intermediate-grade histology among the elderly. In the Danish registry, the histological grades were evenly distributed. In addition, the distribution of localisation was significantly different in the Danish population (more extranodal localisation, mostly stomach), whereas it was not in this registry. Finally, the distribution of stage was also significantly different in West Denmark, showing more stage I-II disease in the elderly while in the current registry the stages were equally divided among the two age groups. These differences are not easy to explain.
One hundred forty-four of the elderly patients were incompletely staged. Several arguments can be advanced to explain a decision for incomplete staging outside the context of a clinical trial. A diagnostic procedure that does not contribute to the decision of whether and how to treat a patient, especially an elderly one, can induce the responsible specialist to abolish the procedure. The bone-marrow biopsy appeared to play a role herein. Despite incomplete staging the records in this registry showed unknown stage for only eight elderly patients. So the criteria applied for staging in this population-based registry are probably a bit different from those applied in clinical trials.
The comorbidity which rises with age [21] and leads to a changed attitude and lower performance, in combination with age-changing aspects of pharmacokinetics, reduced immune status and bone marrow regeneration, contribute to differences in so-called 'biologic behaviour' and this might explain the conflicting results from retrospective studies on the treatment of elderly patients with NHL [1, 5, 8, 18, 19, [22] [23] [24] . Despite a preponderance of intermediate-grade histology among the elderly in the current population-based registry, 92 patients received no treatment at all. Furthermore, although for the majority chemotherapy was indicated, only a minor fraction was treated with anthracycline-based chemotherapy. The disappointingly low CR% contrasts with that from studies with special treatment protocols for the elderly [2, 3, 19, [25] [26] [27] and also with the results in west Denmark, where 58% of those elderly patients, treated with anthracycline-based chemotherapy in the context of a randomised trial, reached complete remission [4] . Besides a better CR% in the Danish elderly population (10% of whom were treated in a randomised trial) the survival data for the elderly with low-, intermediate-and high-grade histology, respectively 48%, 38% and 22% at seven years [4] , were much better than those obtained in the current registry at five years: 39%, 18% and 9%, respectively. The low percentage (26%) of the elderly in the CCCW-region treated with anthracycline-based chemotherapy, possibly the application of dose-reduction strategies and the use of mitoxantrone instead of an anthracycline, might have contributed to the inferior treatment results with respect to complete remission and overall survival. The subgroups of elderly patients with low-grade/stage I NHL and intermediategrade/extensive NHL did not differ significantly from the younger group in these two respects. For the first subgroup this might be explained by the application of radiotherapy, a treatment modality which resulted in a high CR% in both age groups (elderly 54%: Table 3 ); in the second subgroup the younger patients also fared poorly. The application of full-dose chemotherapy augments the chance of achieving complete remission [5, 19, 24] and in that situation the elderly have, analogous to our study, the same disease-free survival as the younger patients [18, 19, 24, 28] . The use of mitoxantrone, once thought to be equally effective as an anthracycline [2, 8, 27, 29, 30] , has been shown in randomised studies to be inferior [31, 32] and therefore, we did not pool the mitoxantrone-containing regimens with the anthracycline-containing schemes for this analysis.
With respect to the R.E.A.L. Classification there are minor epidemiological differences in comparison with other European centers [33] . For instance, in the CCCW fewer patients have been seen with mantle cell lymphoma (3%-4% versus 7%-8%) and with marginal zone B-cell lymphoma (2%-3% versus 9%-13% in Wiirzburg/ Gottingen and Lyon; in London also 3%), although it is not clear whether high-grade MALT lymphomas in the other centers are incorporated in the marginal zone or diffuse large B-cell lymphomas. In the CCCW high grade MALT lymphomas deserve a separate place with the highest five-year % DFS in both age groups and among the elderly this subtype behaves like follicular grade 1-2 lymphomas. Comparing the treatment results in the CCCW according to WF grading with those by R.E.A.L. subtype it is clear that the WF low grade is represented by follicle center follicular grade 1-2 lymphomas and WF intermediate-grade by diffuse large B-cell lymphomas. This is in accordance with a proposed clinical grouping of R.E.A.L. subtypes into indolent, aggressive and very aggressive lymphomas, where follicular grade 1-2 lymphomas belong to the indolent category and diffuse large lymphomas to the aggressive one [34] . On the other hand, is this subdivision artificial when one looks at the treatment results of patients with mantle-cell lymphoma and peripheral T-cell lymphoma? Although in the elderly CR% and five-year % OS are comparable to those in patients with diffuse large-cell lymphomas, the younger group shows inferior treatment results, leading to the disappearance of statistically significant differences between the two age groups. The same inferior five-year % OS for these two subtypes was found by the NHL Classification Project [35] . The overall survival curves of the elderly shown in Figures lb and lc are more or less the same as the ones from elderly patients with follicular-and diffuse large B-cell lymphoma in the NHL Classification Project [36] .
Treatment-related toxicity contributing to death was the same in both groups. For the elderly, the cause of death was not much different from the one shown in the west Denmark results: during a seven-year observation period (n = 289) lymphoma, treatment-related toxicity and concomitant disease (including 'other malignancies') contributed to death in, respectively, 66%, 5% and 30% [4] . Comparable treatment-related toxicity between the young and the elderly is reported by others [18, 19, 22, 37] in addition to equivalent cause-specific survivals [18, 19, 30] and this supports the proposition that dosereduction strategies for elderly patients should be avoided. However, concomitant disease should be taken into account [1, 8, 22, 23, 32] . The application of hematopoietic growth factor support might contribute to less toxicity [3, 8, 38, 39] .
With respect to the age-adjusted prognostic index for patients with intermediate-grade histology this study confirms the results obtained by the International NHL Prognostic Factors Project [17] . From the current registry it was already known that this index was valid for all malignancy grades regardless of patient age [40] . In comparison with the age-adjusted 1PI (age criterion 60 years) [17] the survival at five years for each index value was inferior in this registry (data not shown). Besides the fact that elderly was defined at 70 years or over in this registry, the inferior survival for each index value is probably also influenced by therapeutic regimens. The IPI Project Group's NHL population was treated according to protocols containing anthracyclines, whereas in the current elderly population the minority was treated with an anthracycline-based regimen. Special treatment schemes for the elderly, containing an anthracycline apparently diminish the influence of the index values on survival [25, 26] . This again supports the use of a treatment strategy in the elderly based on anthracyclines.
In conclusion, this survey of a population-based registry emphasises the importance of treatment with the objective of achieving complete remission in elderly patients with NHL. Although the overall survival in the elderly is inferior to that in younger patients, the disease-free survival does not differ significantly. The most probable explanation for the inferior overall survival seems to be the fear of increased toxicity, and thus the application of presumed less toxic therapeutic regimens. On the other hand, all diagnosed patients are included and this also influences treatment results. The elderly patient in a broad sense deserves the best available treatment and hence a better outcome, which can be expected from entering him or her in treatment protocols or, even better, clinical trials.
* Appendix
The following hospitals, internist-oncologists, and patbologists in the CCCW NHL registry participated in this study
